Gene therapy has generated exceptional excitement and interest over its potential for over three decades, but actual clinical progress has been painfully slow and frustrating. Bluebird Bio (NASDAQ:BLUE) (and I am choosing to capitalize the name, even though it is officially lower case) may be on its way to transforming at least part of the dreams and hopes of gene therapy into reality.
Bluebird has developed a platform that management believes will allow the company to deliver therapies via lentivirus vectors to treat single-gene rare/orphan disorders. The company's lead compound addresses a small market, but the second could be a potential billion-dollar therapy. The risks here are definitely elevated, but Bluebird may be in the early days of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|